February 11, 2019

Uptick Newswire Hosts CytoDyn Inc. on Their Stock Day Podcast to Discuss Revenue Expectations for 2020

PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 coreceptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.

Dr. Pourhassan shared that the Company's potential success in the treatments of cancer and HIV could represent a paradigm shift in the medical community, the data simply needs to be shown through human trials for various cancer indications, as they already have for HIV.

Jolly then asked for an update on the Company's recent press release regarding their BLA application with the FDA for a combination therapy for HIV. Dr. Pourhassan shared that the company had discussions with the FDA in regards to the Company's first BLA submission timeline and requirements.

Jolly then asked Dr. Pourhassan what distinguishes the Company from others in the biotechnology space. Dr. Pourhassan explained that the Company is currently exploring several innovative treatments for immune-mediated diseases and shared that he believes 2019 could be a very exciting year. "We believe we're going to make a lot of noise and hopefully introduce new therapies to the medical community and bring value to our stockholders.

Dr. Pourhassan closed by encouraging listeners to check out the Company through their website and follow their enthusiasm for potentially an exciting year in 2019.

To hear more about **CytoDyn Inc.** and listen to the full interview from Dr. Nader Pourhassan, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-dr-nader-pourhassan-of-cytodyn-inc-otcqb-cydy-4/

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first half of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and initiated a clinical trial with leronlimab in metastatic triple-negative breast cancer in 2018. More information is at www.cytodyn.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such

statements due to risks and uncertainties including: (i) the sufficiency of the Company's cash position, (ii) the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv) the Company's ability to enter into partnership or licensing arrangements with third parties, (v) the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company's ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company's clinical trials, (viii) the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:
Nader Pourhassan, Ph.D.
President & CEO
360-980-8524
npourhassan@cytodyn.com

About Uptick Newswire and the "Stock Day" Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its "Stock Day" Podcast, which is the number one radio show of its kind in America. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Uptick receives a fee for its services from CytoDyn for Corporate Communications.

SOURCE:
Uptick Newswire
602-441-3474
https://upticknewswire.com/

Source: CytoDyn, Inc.